You can watch an Elizabeth Holmes documentary on major streaming services: "The Inventor: Out for Blood in Silicon Valley" (HBO, 2019) streams on Max and is available to rent or buy on Prime Video and Apple TV, while "Bad Blood" is the book, not a documentary, and the 2022 Hulu limited series "The Dropout" is a dramatization available on Hulu and Disney+ internationally. Availability shifts by region and licensing window, so verify the listing on your platform before subscribing.
The deeper story behind these films is not the woman but the assay. Theranos claimed a fingerstick of blood could run dozens of tests faster and cheaper than a venous draw. Understanding why that claim strained the limits of analytical chemistry explains why the documentaries feel less like character studies and more like post-mortems on a measurement system.
How a Fingerstick Becomes a Result
A capillary fingerstick yields roughly 100 to 300 microliters of blood, and that sample is a mixture of whole blood, interstitial fluid, and sometimes hemolyzed cells. Laboratories that use venous draws collect 3 to 10 milliliters in tubes with controlled anticoagulants, then centrifuge to separate plasma or serum. Theranos's "Edison" devices reportedly accepted small volumes and attempted immunoassays and chemistry reactions in miniature cartridges.
The mechanism matters because every assay has a signal-to-noise floor. A sandwich immunoassay detects an analyte by binding it between two antibodies and reading a fluorescent or chemiluminescent signal. Shrinking the reaction volume shrinks the signal proportionally, while background noise and pipetting error do not shrink as neatly. A 2016 review published in the journal Clinical Chemistry and Laboratory Medicine flagged that capillary samples and small volumes introduce preanalytical variability that can rival the analyte concentration itself.
Plainly: a small drop of blood is not simply a smaller version of a big tube. It carries different cellular debris, different dilution, and less room for error.
Quantified Context: What Laboratory Standards Demand
Clinical laboratories in the United States operate under the Clinical Laboratory Improvement Amendments, or CLIA, which set accuracy and proficiency testing requirements. For many common immunoassays, acceptable total error is often within roughly 10 to 20 percent of the reference value, depending on the analyte and the governing proficiency program (CLIA). The FDA has cleared specific devices for fingerstick use only when the manufacturer demonstrates equivalence to venous results in validation studies.
Theranos's own published validation, a 2015 paper in the Journal of Clinical Investigation by Holmes and colleagues, presented concordance data. Subsequent reporting by Carreyrou and investigations raised questions about whether the devices actually ran the tests versus commercial analyzers. The documentaries dramatize this gap between claimed and verified performance. The takeaway is regulatory, not personal: a diagnostic claim requires method comparison, precision studies, and interference testing before it reaches patients.
Where the Edge Cases Live
Small-volume assays fail in predictable places. Hemolysis from a tight fingerstick releases potassium and lactate dehydrogenase, inflating those results. Tissue fluid dilution can lower concentrations of large molecules that do not cross capillary walls easily. Coagulation tests are especially sensitive because they depend on precise ratios of calcium, citrate, and clotting factors.
These are not exotic scenarios. They are everyday reasons why a laboratory rejects a hemolyzed sample or redraws a vein. A documentary cannot test a cartridge, but it can show what happens when a company skips the rejection step. The films' most useful contribution is illustrating that quality control is not bureaucracy; it is the mechanism that catches these failures before a patient does.
Misconceptions the Films Invite
A frequent misconception is that the documentaries "prove" Theranos technology never worked at all. Reporting and testimony indicate some tests ran on commercial analyzers and some Edison results existed, but the central issue was that validation and disclosure did not support the marketing claims. The distinction between "did not work as advertised" and "never produced any result" is legally and scientifically meaningful.
A second misconception treats the story as a pure fraud parable. The professional caveat is that the underlying idea, microfluidic point-of-care testing, is real and commercially active. Companies sell cartridge-based assays for infectious disease and coagulation today. The failure was not the concept; it was claiming validated performance before evidence existed.
Comparison of Viewing Options
| Title | Year | Format | Where to watch (US) | Scientific focus |
|---|---|---|---|---|
| The Inventor: Out for Blood in Silicon Valley | 2019 | Documentary | Max; rent/buy Prime Video, Apple TV | Device claims, lab practices |
| The Dropout | 2022 | Dramatized series | Hulu; Disney+ internationally | Character and corporate arc |
| 60 Minutes: Theranos segment | 2018 | News segment | CBS News streaming | Patient testimony, reporting |
| Bad Blood (audiobook) | 2018 | Book/audio | Audible, libraries | Investigative detail |
Availability and pricing change with licensing, so confirm on the platform. None of these are peer-reviewed sources; treat them as journalism and drama, and read the primary regulatory documents for the technical record.
Practical Actions for Curious Viewers
Pick the format that matches your goal: documentary for the science and lab context, dramatization for the human story. Check the streaming listing the day you plan to watch; these titles rotate between subscription and rental tiers. Pair the film with one primary source, such as the FDA's published statements on Theranos, to separate narrative from record. If you work in a lab or clinic, use the film as a teaching case on method validation and preanalytical error. Red flag: any vendor claim of "one drop, many tests" without published method comparison against venous standards. Red flag: a device marketed to consumers before peer-reviewed validation and regulatory clearance.
Limitations and What the Record Cannot Tell You
Documentaries are edited narratives, not audit trails. They cannot establish which specific tests ran on which instrument on a given day. Much of the technical detail remains sealed in litigation records or summarized secondhand. The films also omit the slow, unglamorous work of method validation, which is where the real scientific lessons sit.
Streaming catalogs are not scientific evidence, and availability tells you nothing about accuracy. Treat any documentary as a starting point for primary sources, including regulatory correspondence and peer-reviewed method studies. The stable lesson is procedural: diagnostic claims require independent validation, transparent reporting, and comparison to accepted reference methods before they reach patients. That principle does not expire with a licensing window.
This article is general educational information, not a diagnosis, treatment plan, or investment recommendation. It does not promise any outcome from watching these films or using any testing technology. For questions about laboratory testing or a medical decision, consult a qualified local professional.